Regulus Therapeutics Announces Update On Preclinical Studies In Amyotrophic Lateral Sclerosis In Collaboration With Researchers From Harvard's Brigham And Women's Hospital
Portfolio Pulse from Happy Mohamed
Regulus Therapeutics (NASDAQ:RGLS) announced an update on its preclinical studies for the treatment of Amyotrophic Lateral Sclerosis (ALS) in collaboration with Harvard's Brigham and Women's Hospital. The program has advanced to lead compound evaluation in preclinical in vivo models, with preliminary data expected in the second half of 2023.
June 20, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regulus Therapeutics advances in preclinical studies for ALS treatment in collaboration with Harvard's Brigham and Women's Hospital, with preliminary data expected in H2 2023.
The advancement of Regulus Therapeutics' preclinical studies for ALS treatment in collaboration with Harvard's Brigham and Women's Hospital is a positive development for the company. This progress indicates that the company is moving forward in its research, which could potentially lead to a new treatment for ALS patients. As a result, this news is likely to have a positive short-term impact on RGLS stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100